JP2022512900A5 - - Google Patents

Info

Publication number
JP2022512900A5
JP2022512900A5 JP2021523897A JP2021523897A JP2022512900A5 JP 2022512900 A5 JP2022512900 A5 JP 2022512900A5 JP 2021523897 A JP2021523897 A JP 2021523897A JP 2021523897 A JP2021523897 A JP 2021523897A JP 2022512900 A5 JP2022512900 A5 JP 2022512900A5
Authority
JP
Japan
Prior art keywords
represented
formula
bifunctional compound
group
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512900A (ja
JP7712867B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059401 external-priority patent/WO2020092907A1/en
Publication of JP2022512900A publication Critical patent/JP2022512900A/ja
Publication of JP2022512900A5 publication Critical patent/JP2022512900A5/ja
Application granted granted Critical
Publication of JP7712867B2 publication Critical patent/JP7712867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523897A 2018-11-02 2019-11-01 アセチル化ライター阻害剤の開発およびその使用 Active JP7712867B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754934P 2018-11-02 2018-11-02
US62/754,934 2018-11-02
PCT/US2019/059401 WO2020092907A1 (en) 2018-11-02 2019-11-01 Acetylation writer inhibitor development and uses thereof

Publications (3)

Publication Number Publication Date
JP2022512900A JP2022512900A (ja) 2022-02-07
JP2022512900A5 true JP2022512900A5 (cg-RX-API-DMAC7.html) 2022-11-08
JP7712867B2 JP7712867B2 (ja) 2025-07-24

Family

ID=70463920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523897A Active JP7712867B2 (ja) 2018-11-02 2019-11-01 アセチル化ライター阻害剤の開発およびその使用

Country Status (8)

Country Link
US (2) US12428412B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873898B1 (cg-RX-API-DMAC7.html)
JP (1) JP7712867B2 (cg-RX-API-DMAC7.html)
CN (1) CN112969696B (cg-RX-API-DMAC7.html)
AU (1) AU2019371400B2 (cg-RX-API-DMAC7.html)
CA (1) CA3118597A1 (cg-RX-API-DMAC7.html)
ES (1) ES3038078T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020092907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN111217802B (zh) * 2018-11-27 2021-10-08 海创药业股份有限公司 一类组蛋白乙酰化酶p300抑制剂及其用途
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN113646002A (zh) * 2019-02-27 2021-11-12 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
EP3986470A4 (en) * 2019-06-18 2023-10-04 Dana-Farber Cancer Institute, Inc. TARGETED SMALL MOLECULE BROMO/ACETYL PROTEINS AND THEIR USES
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
AU2021316053A1 (en) 2020-07-30 2023-03-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
CN116507333B (zh) * 2020-08-27 2025-05-09 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
EP4304572A4 (en) * 2021-03-09 2025-02-12 Dana-Farber Cancer Institute, Inc. EP300 DEGRADER AND USES THEREOF IN NEUROBLASTOMA
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス, インコーポレイテッド Irak4分解剤およびその合成
CN116375717B (zh) * 2021-12-30 2025-10-28 成都先导药物开发股份有限公司 螺环化合物及其双功能化合物和用途
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
GB202209404D0 (en) * 2022-06-27 2022-08-10 Univ Of Sussex Compounds
JP2025137900A (ja) * 2022-08-10 2025-09-25 住友ファーマ株式会社 第4級炭素で置換された3級アミド誘導体
JP7856847B2 (ja) * 2022-09-07 2026-05-11 成都先導薬物開発股▲フン▼有限公司 スピロ化合物及びその用途
CN119255996B (zh) * 2022-09-08 2026-04-24 成都先导药物开发股份有限公司 螺环化合物及其用途
WO2024064358A1 (en) * 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AU2023358062A1 (en) 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
CN116178339B (zh) * 2023-02-20 2024-08-06 杭州医学院 以含氧烷烃为连接链的hdac降解剂及其制备方法和应用
GB202302941D0 (en) 2023-02-28 2023-04-12 Tocris Cookson Ltd Proteolysis-targeting chimeras
AU2024395784A1 (en) 2023-12-07 2026-06-11 Pfizer Inc. Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b
WO2026088071A1 (en) 2024-10-23 2026-04-30 Pfizer Inc. Substituted fused heteroaryl lactam compounds
WO2026154417A1 (en) 2025-01-17 2026-07-23 Pfizer Inc. Fused heterocyclic amide/sulfonamide compounds as agonists of the calcitonin/amylin receptors for the treatment of obesity
WO2026159633A1 (en) 2025-01-24 2026-07-30 Pfizer Inc. 4-(2-(dimethylamino)-2-oxoethyl)-3-methyl-5-oxo-2,3,4,5-tetrahydrobenzofuro[2,3-f][1,4]oxazepine-3-carboxamide compounds and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US20160235716A1 (en) 2014-09-18 2016-08-18 Abbvie Inc. Spirocyclic hat inhibitors and methods for their use
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CN109562113A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
MX2019004950A (es) * 2016-10-28 2019-09-26 Icahn School Med Mount Sinai Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3986470A4 (en) * 2019-06-18 2023-10-04 Dana-Farber Cancer Institute, Inc. TARGETED SMALL MOLECULE BROMO/ACETYL PROTEINS AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2020506951A5 (cg-RX-API-DMAC7.html)
KR100346795B1 (ko) 헤테로원자-포함 리간드 및 이의 금속 착화합물
IL312845B1 (en) Extacan derivatives, charge-linkers, and their conjugates
JP2023551355A (ja) 抗腫瘍化合物並びにその調製方法及び使用
JP2022166014A5 (cg-RX-API-DMAC7.html)
JP2019534034A5 (cg-RX-API-DMAC7.html)
JP2006511534A5 (cg-RX-API-DMAC7.html)
JP2010508359A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2022543231A5 (cg-RX-API-DMAC7.html)
JP2018511628A5 (cg-RX-API-DMAC7.html)
CA2479109A1 (en) Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
JP2010535713A5 (cg-RX-API-DMAC7.html)
JP3187535B2 (ja) 医薬的に活性なヒドラジン誘導体およびその製造方法
JP2021510376A5 (cg-RX-API-DMAC7.html)
JP2022549510A5 (cg-RX-API-DMAC7.html)
JP2014500870A5 (cg-RX-API-DMAC7.html)
JPS635033A (ja) 化合物標的化組成物
JP2018516243A5 (cg-RX-API-DMAC7.html)
JP2021503915A5 (cg-RX-API-DMAC7.html)
JP2023533203A5 (cg-RX-API-DMAC7.html)
JP2021525730A5 (cg-RX-API-DMAC7.html)
JP2021530444A5 (cg-RX-API-DMAC7.html)
JP2024504471A5 (cg-RX-API-DMAC7.html)
JP2024513505A5 (cg-RX-API-DMAC7.html)